secwatch.observer — SEC 8-K summary
======================================

Issuer:     BICYCLE THERAPEUTICS PLC (BCYC)
CIK:        0001761612
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0001104659-23-026349
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bicycle Therapeutics reports FY2022 net loss of $112.7M; cash $339.2M, runway into 2025
--------------------------------------------------------------------------------

- Net loss of $30.0M in Q4 2022 ($1.01/share) and $112.7M for FY2022 ($3.80/share), vs $18.0M and $66.8M in prior year.
- Cash and equivalents $339.2M at Dec 31, 2022, down from $438.7M; expected to fund operations into 2025.
- R&D expenses rose to $81.6M in FY2022 from $44.9M, driven by clinical programs for BT5528, BT8009, and TICA platform.
- BT8009 granted FDA Fast Track Designation for urothelial cancer; Phase II expansion initiated with RP2Ds established.
- BT5528 continues in dose expansion; BT7480 in dose escalation; pipeline updates expected later in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761612/000110465923026349/0001104659-23-026349-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761612/000110465923026349/tm237668d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-026349

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer